Effectiveness of different dietary strategies in the management of obesity and obesity-related comorbidities

Jamka, Małgorzata; Wasiewicz-Gajdzis, Maria; Walkowiak, Jarosław

doi:10.20883/medical.e523

Cited by 4 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As epidemiological studies have shown an incompatible association between ovarian cancer and indicated that obesity and severe obesity increase the risk of ovarian cancer [8]. Even though it is found that the effectiveness of different dietary strategies in the management of obesity and obesity-related complications have shown heterogeneous findings, none of our patients was on diet [9].…”

Section: Introductionmentioning

confidence: 69%

A retrospective analysis of haematological side effects of olaparib in excess-weight and normal BMI patients with ovarian cancer

Stanislawiak-Rudowicz,

Szałek,

Adamiak

et al. 2024

Rep Pract Oncol Radiother.

View full text Add to dashboard Cite

Background: Olaparib is the first poly(ADP-ribose) polymerase inhibitor approved in Europe for the treatment of platinum-sensitive patients with newly diagnosed or recurrent platinum-sensitive ovarian cancer with a confirmed BRCA mutation or homologous recombination deficiency (HRD). Epidemiological studies have shown an incompatible association between ovarian cancer and obesity, but there have also been scientific reports indicating that obesity, especially severe obesity, increases the risk of ovarian cancer. Olaparib has a wide range of side effects, especially anaemia and neutropenia, which may lead to dose reduction or therapy discontinuation. Therefore, therapeutic drug monitoring (TDM) is recommended. The aim of the study was a retrospective analysis of threshold value of the trough concentration of olaparib (C trough ) and haematological adverse reactions after olaparib treatment (300 mg/12 h) in excess-weight and normal body mass index (BMI) patients with ovarian cancer. Materials and methods:The pilot study was conducted on 38 ovarian cancer patients who were divided into two groups: I -normal BMI patients (BMI = 18.5-24.9 kg/m 2 ; n = 14), II -excess-weight patients, i.e. overweight and obese patients (BMI ≥ 25 kg/m 2 ; n = 24). The severity of neutropenia and anaemia was graded according to the Common Terminology Criteria for Adverse Events (CTCAE v5.0). The values of the mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC), and red blood cell distribution width (RDW) parameters were also taken into account. HPLC-UV method (λ = 254 nm) was applied to measure olaparib plasma concentrations.Results: There were no statistically significant differences in olaparib C trough between the groups -1602.86 vs. 1567.40 ng/mL (p = 0.9156). However, the overweight and obese patients had slightly higher dose/kg-adjusted olaparib C trough -204.17 vs. 159.32 ng/mL/mg/kg. The incidence of grade 1 anaemia in the groups was as follows: I -42.86%, II -41.67%. Grade 2 and 3 anaemia was observed only in group II -4.17% and 8.33%, respectively. The incidence of neutropenia in the groups of patients was as follows: grade 1: group I -21.43%, group II -20.83%; grade 2: group I -7.14%, group II -4.17%. Conclusions:The incidence of haematological adverse reactions to olaparib, such as neutropenia and grade 1 anaemia in the group of overweight and obese patients was the same as in the normal BMI group. The overweight and obese patients were characterised by higher severity of haematological adverse reactions to olaparib and slightly higher dose/kg-adjusted olaparib C trough . After one month of treatment with olaparib the overweight and obese patients had significantly lower red blood cells (RBC) and haemoglobin (Hgb) levels than the patients with normal BMI, which may indicate that anaemia develops faster in this group of patients.

show abstract

Section: Introductionmentioning

confidence: 69%

A retrospective analysis of haematological side effects of olaparib in excess-weight and normal BMI patients with ovarian cancer

Stanislawiak-Rudowicz,

Szałek,

Adamiak

et al. 2024

Rep Pract Oncol Radiother.

View full text Add to dashboard Cite

show abstract

Effect of a high-fat high-fructose diet on the composition of the intestinal microbiota and its association with metabolic and anthropometric parameters in a letrozole-induced mouse model of polycystic ovary syndrome

Pieczyńska-Zając,

Malinowska,

Pruszyńska-Oszmałek

et al. 2024

Nutrition

View full text Add to dashboard Cite

Control of Cholesterol Metabolism Using a Systems Approach

Formanowicz

Radom

Rybarczyk

et al. 2022

Biology

View full text Add to dashboard Cite

Cholesterol is an essential component of mammalian cells and is involved in many fundamental physiological processes; hence, its homeostasis in the body is tightly controlled, and any disturbance has serious consequences. Disruption of the cellular metabolism of cholesterol, accompanied by inflammation and oxidative stress, promotes the formation of atherosclerotic plaques and, consequently, is one of the leading causes of death in the Western world. Therefore, new drugs to regulate disturbed cholesterol metabolism are used and developed, which help to control cholesterol homeostasis but still do not entirely cure atherosclerosis. In this study, a Petri net-based model of human cholesterol metabolism affected by a local inflammation and oxidative stress, has been created and analyzed. The use of knockout of selected pathways allowed us to observe and study the effect of various combinations of commonly used drugs on atherosclerosis. The analysis results led to the conclusion that combination therapy, targeting multiple pathways, may be a fundamental concept in the development of more effective strategies for the treatment and prevention of atherosclerosis.

show abstract

Effectiveness of different dietary strategies in the management of obesity and obesity-related comorbidities

Cited by 4 publications

References 22 publications

A retrospective analysis of haematological side effects of olaparib in excess-weight and normal BMI patients with ovarian cancer

A retrospective analysis of haematological side effects of olaparib in excess-weight and normal BMI patients with ovarian cancer

Effect of a high-fat high-fructose diet on the composition of the intestinal microbiota and its association with metabolic and anthropometric parameters in a letrozole-induced mouse model of polycystic ovary syndrome

Control of Cholesterol Metabolism Using a Systems Approach

Contact Info

Product

Resources

About